We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Recombinant Immunoassay Diagnoses Human Fascioliasis

By LabMedica International staff writers
Posted on 03 Oct 2013
Image: Adult of Fasciola hepatica stained with carmine (Photo courtesy of US Centers for Disease Control).
Image: Adult of Fasciola hepatica stained with carmine (Photo courtesy of US Centers for Disease Control).
The current diagnosis of human fascioliasis involves the detection of eggs in the stool, however, eggs are not observed during the acute phase when the parasite is migrating through the tissues.

A human immune response to Fasciola antigens occurs early in infection, therefore, an immunological method such as an enzyme-linked immunosorbent assay (ELISA) may be a more reliable, easy and cheap means to diagnose human fascioliasis than coprological analysis.

Scientists from McGill University (Montreal, QC, Canada) collected serum samples from 93 Cuban individuals that were coprologically positive for eggs of F. hepatica and clinically diagnosed in the hospital. Samples were also collected from 72 Cuban and 63 Canadian individuals that were shown to be negative for Fasciola infection, and 158 serum samples obtained from individuals infected with other parasitic diseases. The ELISA test was optimized using a recombinant form of the major F. hepatica cathepsin L1 protease antigen (FhCL1).

The ELISA test using anti-total immunoglobulin G (IgG) secondary antibody gave 99.99% specificity and also exhibited 99.99% sensitivity for identifying infected individuals. The results showed that absorbance readings obtained with sera from patients infected with parasites other than F. hepatica closely matched that obtained with the negative control samples. The investigators found that using 0.55 optical density (OD) units as cut-off with anti-total IgG as secondary antibody, the test can discriminate between F. hepatica patients and all other infections examined.

The authors concluded that their standardized ELISA test using a highly stable recombinant form of cathepsin L1, FhCL1, exhibits high sensitivity and specificity and with no cross-reaction with other parasitic diseases. High production of this enzyme can be obtained by purification of Pichia pastoris culture medium, which provides sufficient quantities of material to supply diagnostic centers for mass screening in regions where human fascioliasis is prevalent. The study was published on September 19, 2013, in the journal Public Library of Science Neglected Tropical Disease.

Related Links:

McGill University


Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
New
Gold Member
Platelet Function Analyzer
PL-12
Platinum Member
Integrated Biochemical & Immunological System
Biolumi CX Solution X10+C10
Automated Urinalysis Solution
UN-9000

Channels

Clinical Chemistry

view channel
Image: LVOne uses blood-based biomarkers to detect stroke and identify large vessel occlusion before hospital arrival, providing objective results earlier than traditional assessments. (Photo courtesy of UpFront Diagnostics)

First-of-Its-Kind Rapid Blood Test Gains CE Mark to Support Prehospital Stroke Triage

Rapid stroke identification before hospital arrival is critical because treatment efficacy declines with every minute of delay. However, definitive assessment typically requires hospital-based imaging,... Read more

Molecular Diagnostics

view channel
Image Credit: iStock

Mpox Analysis Reveals Substantial Suspected False Positives Associated with Contamination

Reliable confirmation of mpox can be difficult where multiple rash-causing illnesses co-circulate and laboratory capacity is limited. Although PCR is central to case detection, contamination during specimen... Read more

Immunology

view channel
Image: Aptiva utilizes particle-based multi-analyte technology (PMAT) (Photo courtesy of Werfen)

Werfen Expands Automated APS Testing with FDA-Cleared and CE-Marked IgA Reagent

Antiphospholipid syndrome (APS) is an autoimmune disorder associated with thrombosis and pregnancy complications, but its symptoms can overlap with those of other conditions, complicating diagnosis.... Read more

Pathology

view channel
Image: A new study demonstrates that vascular features in colorectal tumors could serve as prognostic biomarkers of disease outcome. (Image Credit: iStock)

Tumor Blood Vessel Features May Help Predict Colorectal Cancer Survival

Colorectal cancer outcomes vary widely, and tumor biology remains a key determinant of prognosis. Because neoplasms depend on a vascular supply, differences in intratumoral vessels may influence survival.... Read more

Technology

view channel
Image: ADLM recommends that emerging AI tools follow the same professional oversight, quality, validation, and monitoring standards as traditional clinical testing within CLIA’s existing framework (Image Credit: Adobe Stock)

ADLM Calls for CLIA Updates to Support Safe AI Use in Laboratory Medicine

Clinical laboratories increasingly use artificial intelligence to verify, interpret, and report results, but safeguards under the Clinical Laboratory Improvement Amendments (CLIA) were designed in 1992.... Read more

Industry

view channel
Image: Central to the collaboration is the Enhanced Liver Fibrosis (ELF) test, a noninvasive blood test authorized in the U.S. to assess disease progression risk in patients with advanced fibrosis due to MASH and support patient management decisions. (Photo courtesy of Siemens Healthineers)

Siemens Healthineers and Novo Collaborate to Expand Access to Noninvasive Liver Testing

Metabolic dysfunction‑associated steatotic liver disease (MASLD) and its progressive form, metabolic dysfunction‑associated steatohepatitis (MASH), affect millions and are linked to obesity, type 2 diabetes,... Read more